The Saudi Pharmaceutical Industries and Medical supplies Company (SPIMACO ADDWAEIH) has signed a memorandum of understanding with the German company CureVac, a leading company in biomedical researches, to provide a vaccine for the coronavirus in Saudi Arabia.

According to the agreement, SPIMACO ADDWAEIH will import and distribute the vaccine in the Kingdom, as well as representing before the government authorities in the registration of the vaccine and to obtain the necessary approvals from the Ministry of Health and the Saudi Food and Drug Authority for all regulatory requirements relating to the sale, distribution and use of the vaccine.

SPIMACO ADDWAEIH may expand the project to include Kuwait, the United Arab Emirates, Bahrain and Oman.

Dr. Mohammed Al Sultan, CEO SPIMACO ADDWAEIH, confirmed that this memo is in line with the efforts exerted by the government of Custodian of the Two Holy Mosques King Salman bin Abdulaziz and Crown Prince Mohammed bin Salman to confront the pandemic and to continue in achieving the company strategy toward achieving drug security in the Kingdom.

Al Sultan said CureVac conducted successful Phase I dose finding clinical trials and reached promising results to proceed to a phase IIb/III clinical trial, aiming to submit the registration file European Medicines Agency (EMA) during the first quarter of 2021 according to the plan set by the company. The vaccine is characterized by its routine storage conditions of 2-8 degrees Celsius

Since the beginning of the pandemic in the Kingdom, SPIMACO ADDWAEIH has worked to maintain the Kingdom’s drug security and the company has increased its production capacity to cover the high demand in the local market.